Amidst the wave of precision medicine, the performance of drug carriers directly determines the success or failure of therapeutic interventions. Traditional pharmaceuticals are often constrained by issues such as rapid metabolism and significant toxic side effects; however, precipitated silica—by virtue of its immense specific surface area, ordered mesoporous structure, and exceptional adsorption capacity—has emerged as an ideal platform for constructing highly efficient drug carriers. By precisely engineering functional drug ions into its mesopores, precipitated silica facilitates both the sustained release and targeted delivery of pharmaceuticals, thereby paving new pathways for modern pharmacy.

The "nanoscale warehouse" effect of precipitated silica stems from its unique mesoporous architecture. Its specific surface area can reach an impressive 800–1200 m²/g, with pore diameters continuously tunable within the 2–50 nm range, forming a regular network of interconnected channels. This structure provides ample loading space for drug molecules; taking hydrophobic drugs such as ibuprofen as an example, drug precursors can be introduced into the silica pores via a sol-gel method. The drug molecules subsequently form hydrogen bonds or engage in van der Waals interactions with the silanol groups on the pore walls, achieving a drug loading capacity exceeding 30%. Furthermore, the "molecular sieve" effect of these channels effectively prevents drug aggregation, ensuring that the drug remains uniformly dispersed in a single-molecule state—thereby circumventing the issues of drug crystallization and precipitation often encountered in traditional pharmaceutical formulations.

In terms of sustained-release performance, precipitated silica demonstrates exceptional capabilities through its "controlled diffusion" mechanism. The release of drug molecules from the mesopores adheres to Fickian diffusion principles; by precisely modulating pore size, channel tortuosity, and surface chemical properties, the drug release rate can be accurately controlled. For instance, MCM-41 type precipitated silica—synthesized using cetyltrimethylammonium bromide (CTAB) as a template—features pore diameters of 3–4 nm. This structure enables a sustained release duration for ibuprofen exceeding 24 hours, a performance far superior to the 4–6 hours typically observed with conventional pharmaceutical formulations. This "continuous drug supply" characteristic not only reduces the required frequency of administration but also maintains stable drug concentrations within the bloodstream, thereby significantly enhancing therapeutic efficacy.

The realization of targeted drug delivery relies upon the "functionalization and surface modification" of the precipitated silica. The abundant silanol groups present on its surface serve as anchoring points, facilitating the grafting of targeting molecules—such as folic acid or antibodies—via silane coupling agents. In the context of tumor therapy, grafting folic acid onto the surface of drug-loaded precipitated silica enables active targeted drug delivery by leveraging the folic acid receptors that are overexpressed on the surface of tumor cells. *In vitro* experiments have demonstrated that the cellular uptake rate of these targeted silica carriers by tumor cells is more than five times higher than that of non-targeted carriers, thereby significantly reducing toxic side effects on normal cells. Furthermore, by modifying the pore openings with pH-responsive linkages (such as hydrazone bonds), "smart drug release" within the tumor microenvironment can be achieved; under acidic conditions ranging from pH 5.0 to 6.5, the drug release rate increases threefold, further enhancing targeting specificity.

Biocompatibility and safety constitute the key advantages of precipitated silica when utilized as a drug carrier. Its non-toxic, odorless, and physiologically inert characteristics ensure that it does not trigger immune responses *in vivo* and can be effectively eliminated from the body via renal excretion. Modified precipitated silica has demonstrated exceptional performance in vaccine development, enhancing antigen adsorption capacity while preserving biological activity, thereby offering novel perspectives for the creation of new-generation vaccines.

Ranging from the precise control of mesoporous structures to sophisticated surface functionalization, precipitated silica is emerging as a "stealth weapon" in the field of drug delivery, distinguished by its comprehensive advantages: serving as a "nanoscale reservoir," enabling "controllable diffusion," and facilitating "targeted recognition." It not only holds the key to resolving the complex challenges associated with sustained drug release and targeted delivery but also provides a robust material foundation for the realization of precision medicine.